Last reviewed 2026-04-23 · How we verify

Fasedienol Nasal Spray

Fasedienol is a NMDA receptor antagonist administered as a nasal spray for rapid-onset treatment of depression.

Fasedienol is a NMDA receptor antagonist administered as a nasal spray for rapid-onset treatment of depression. Used for Major depressive disorder (Phase 3), Treatment-resistant depression (exploratory).

At a glance

Mechanism of action

Fasedienol acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor subtype implicated in depression pathophysiology. By blocking NMDA receptor signaling, it is hypothesized to rapidly restore synaptic plasticity and produce fast-acting antidepressant effects. The nasal spray formulation enables direct brain delivery and rapid systemic absorption, potentially providing faster symptom relief compared to oral antidepressants.

Approved indications

• Major depressive disorder (Phase 3)
• Treatment-resistant depression (exploratory)

Common side effects

• Dissociation
• Dizziness
• Nasal irritation
• Headache

Key clinical trials

• A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PHASE2)
• Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) (PHASE3)
• Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Fasedienol Nasal Spray CI brief — competitive landscape report
• Fasedienol Nasal Spray updates RSS · CI watch RSS
• VistaGen Therapeutics, Inc. portfolio CI